OncoCyte Corp reports results for the quarter ended in December - Earnings Summary

Insight Molecular Diagnostics

10/03/2022 22:37

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of 39
cents​​ per share for the quarter ended in December. The mean
expectation of seven analysts for the quarter was for a loss
of 13 cents per share.
    * Revenue rose 613.5% to $3.59 million from a year ago; 
analysts
expected $3.63 million. 
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * OncoCyte Corp shares had fallen by 40.1% this quarter.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 10 at 10:36 p.m.  ​All
figures in US dollars unless otherwise stated